| Nov 18 |
Why Merck rolled the dice on an ‘unbelievable’ early-stage brain cancer drug
|
| Nov 15 |
How analysts are reacting to RFK Jr. as Trump's HHS pick
|
| Nov 15 |
Merck Inks $3.3B Licensing Deal With Chinese Biotech for Cancer Therapy
|
| Nov 15 |
The Strong Earnings Posted By Merck (NYSE:MRK) Are A Good Indication Of The Strength Of The Business
|
| Nov 15 |
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
|
| Nov 15 |
Vaccine stocks drop on concerns about RFK Jr. heading HHS (update)
|
| Nov 15 |
Want dividend safety, consistency, growth, and a yield? See these 10 names
|
| Nov 15 |
Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of.
|
| Nov 15 |
Merck Keytruda endorsed in EU for rare form of cancer
|
| Nov 15 |
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)
|
